Why commercial sponsors should continue to choose the UK when delivering clinical research
Uncategorized
Borrowed time?
The NHS’ next chapter – managed decline, or new opportunities for pharma?
A new flame
In a rapidly evolving healthcare landscape, digitisation can transform pharma’s quest to improve mental health outcomes
The human condition
How do we make rare disease clinical trials more human?
Empire strikes back
Therapeutic cancer vaccines can destroy our most formidable enemy
Centre of the pharmaverse
Adapting to the new normal includes a wider understanding of the challenges in clinical trial decentralisation
Listening project
From the briefing room – how to future-proof healthcare comms
Taking our chances
Decarbonising the pharma supply chain and the journey to net zero
Funky trainers on a mission
‘Women in Pharma’ is a new group that’s been making waves on LinkedIn. PharmaTimes caught up with the founders to discover more
Digital dichotomy
The challenge of achieving functioning NHS digital change cost-effectively
Optimise this!
Navigating the maze of NHS medicines optimisation requires a truly joined-up approach
Evolution energised
In an ever-complex regulatory environment – and a rapidly evolving digital landscape –adopting an effective digital transformation strategy is pivotal
Talking the talk
Companies are getting closer to their end users but does industry really understand its customers?
Moving on up
HCP common goals – a deal with the devil or a blessing in disguise?
The holy grail for pharma?
Real-world evidence – is it the sacred answer or a load of hype?
